The Expression of Beclin-1 in Hepatocellular Carcinoma and Non-Tumor Liver Tissue: A Meta-Analysis

The Expression of Beclin-1 in Hepatocellular Carcinoma and Non-Tumor Liver Tissue: A Meta-Analysis

Loading document ...
Loading page ...


Author(s): Zhiqiang Qin, Xinjuan Yu, Jinkun Wu, Mei Lin

Download Full PDF Read Complete Article

DOI: 10.18483/ijSci.1625 140 471 8-14 Volume 7 - Apr 2018


Background Recently, Beclin-1 expression in hepatocellular carcinoma (HCC) and non-tumor liver tissue have been investigated by several studies. However, the results are controversial. The aim of this study was to clarify the role of Beclin-1 in the occurrence of HCC by comparing the difference of Beclin-1 expression between HCC and non-tumor liver tissue. Methods An electronic retrieve for relevant studies was performed in PubMed, EMBASE, China National Knowledge Infrastructure (CNKI), Wan Fang and Chinese VIP databases updated to December 31, 2017. Newcastle-Ottawa-Scale (NOS) was used to assess the quality of the eligible studies. Sensitivity, subgroup, and publication bias analyses were also carried out in this meta-analysis. Statistical analysis was performed by Review Manager 5.3 and STATA 12.0. Results Six high-quality studies with 357 HCC patients were eligible. There was no significant difference of Beclin-1 expression between HCC and non-tumor liver tissue (OR = 2.48, 95%CI = 0.64-9.58, P = 0.19). However, sensitivity analysis showed that Beclin-1 was lower in HCC than in non-tumor liver tissue after omitting Kang et al.’s study (OR = 4.14, 95% CI = 1.75-9.81, P = 0.001), and heterogeneity was not evident (P = 0.14, I² = 43%). Subgroup analysis suggested that heterogeneity may stem from ethnicity. The funnel plot and Egger’s test (P = 0.900) demonstrated that no significant publication bias was present in this meta-analysis. Conclusion This meta-analysis indicated that there was no significant difference of Beclin-1 expression between HCC and non-tumor liver tissue.


Beclin-1, Hepatocellular Carcinoma (HCC), Non-Tumor Liver Tissue, Meta-Analysis, Autophagy


  1. Forner, A., M. Reig, and J. Bruix, Hepatocellular carcinoma. Lancet (London, England), 2018.
  2. Mathew, S., et al., Biomarkers for virus-induced hepatocellular carcinoma (HCC). Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 2014. 26: p. 327-39.
  3. Gomaa, A.I. and I. Waked, Recent advances in multidisciplinary management of hepatocellular carcinoma. World journal of hepatology, 2015. 7(4): p. 673-87.
  4. Eskelinen, E.L. and P. Saftig, Autophagy: a lysosomal degradation pathway with a central role in health and disease. Biochimica et biophysica acta, 2009. 1793(4): p. 664-73.
  5. Brech, A., et al., Autophagy in tumour suppression and promotion. Molecular oncology, 2009. 3(4): p. 366-75.
  6. White, E., The role for autophagy in cancer. The Journal of clinical investigation, 2015. 125(1): p. 42-6.
  7. Qiu, D.M., et al., The expression of beclin-1, an autophagic gene, in hepatocellular carcinoma associated with clinical pathological and prognostic significance. BMC Cancer, 2014. 14: p. 327.
  8. Kang, K.F., et al., Beclin 1 and nuclear factor-kappaBp65 are upregulated in hepatocellular carcinoma. Oncol Lett, 2013. 5(6): p. 1813-1818.
  9. Moher, D., et al., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annals of internal medicine, 2009. 151(4): p. 264-9, w64.
  10. Stang, A., Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European journal of epidemiology, 2010. 25(9): p. 603-5.
  11. Liang, C., et al., Prognostic and clinicopathological value of Nanog in hepatocellular carcinoma: A meta-analysis. Clinica chimica acta; international journal of clinical chemistry, 2018. 477: p. 24-31.
  12. Osman, N.A., D.M. Abd El-Rehim, and I.M. Kamal, Defective Beclin-1 and elevated hypoxia-inducible factor (HIF)-1alpha expression are closely linked to tumorigenesis, differentiation, and progression of hepatocellular carcinoma. Tumour Biol, 2015. 36(6): p. 4293-9.
  13. Al-Shenawy, H.A., Expression of Beclin-1, an autophagy-related marker, in chronic hepatitis and hepatocellular carcinoma and its relation with apoptotic markers. APMIS, 2016. 124(3): p. 229-37.
  14. Guo, X.D., et al., Expression and Clinical Significance of Beclin 1 in Patients with Hepatocellular Carcinoma. Progress in Modern Biomedicine, 2013. 13(1): p. 85-87.
  15. Yang, W., et al., Expression of Beclin1 in Human Hepatocellular Carcinoma and Effects of TGF-β on Proliferation of Hepatocellular Carcinoma Cells. Int J Lab Med, 2015. 36(1): p. 108-109.
  16. Levine, B. and G. Kroemer, Autophagy in the pathogenesis of disease. Cell, 2008. 132(1): p. 27-42.
  17. Mathew, R., et al., Autophagy suppresses tumor progression by limiting chromosomal instability. Genes & development, 2007. 21(11): p. 1367-81.
  18. Yue, Z., et al., Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proceedings of the National Academy of Sciences of the United States of America, 2003. 100(25): p. 15077-82.

Cite this Article:

International Journal of Sciences is Open Access Journal.
This article is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) License.
Author(s) retain the copyrights of this article, though, publication rights are with Alkhaer Publications.

Search Articles

Issue June 2023

Volume 12, June 2023

Table of Contents

World-wide Delivery is FREE

Share this Issue with Friends:

Submit your Paper